ArticleJournal of neuro-oncology2025
ANG peptide-modified exosomes loaded with oleanolic acid target GPX4 for enhanced breast cancer brain metastasis therapy.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeBreast cancer brain metastasis (BCBM) is a major clinical challenge due to the blood-brain barrier (BBB) restricting effective drug delivery, resulting in limited therapeutic options and poor prognosis. This study aims to develop ANG peptide-modified exosomes loaded with oleanolic acid (ANG-Exo-OA) to enhance brain-targeted delivery and investigate its anti-tumor mechanisms through GPX4-mediated ferroptosis in BCBM treatment.
methodsOleanolic acid was encapsulated into mesenchymal stem cell-derived exosomes via electroporation, with ANG peptide conjugated using thiol-maleimide chemistry. ANG-Exo-OA was characterized using nanoparticle tracking analysis, transmission electron microscopy, and Western blot. Biocompatibility was evaluated via cytotoxicity assays, hematoxylin and eosin staining, and serum biochemistry. Brain-targeting efficiency was assessed using an in vitro BBB model and in vivo imaging. Anti-tumor effects and GPX4 pathway involvement were examined in a Luc-labeled MDA-MB-231 BCBM mouse model using Western blot, malondialdehyde, glutathione assays, and GPX4 overexpression rescue experiments. Statistical analyses included t-tests and ANOVA.
resultsANG-Exo-OA exhibited excellent biocompatibility, stability, and enhanced BBB penetration, with significant brain accumulation. It suppressed MDA-MB-231 cell proliferation, migration, and induced apoptosis, accompanied by decreased GPX4 expression and increased lipid peroxidation. In vivo, ANG-Exo-OA reduced tumor growth and promoted ferroptosis, effects reversed by GPX4 overexpression.
conclusionANG-Exo-OA represents a promising therapeutic strategy for BCBM, achieving enhanced brain-targeted delivery and effective GPX4-mediated ferroptosis induction in a TNBC model. While the findings highlight its potential value for BCBM treatment, further studies involving additional breast cancer subtypes and more clinically relevant models are required to determine its broader applicability.
Indexed as
Identifiers
41428269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.